COVID-19 Implications for I-O Patient Management

 View Only
last person joined: 3 months ago 

This discussion board is devoted to conversations directly relevant to clinical care. Example topics include:
• Trends in demographics
• Trends in clinical presentation
• Issues regarding diagnostic testing
• Patient management issues/insights
• Observations on emerging natural history/patterns in clinical complications
• Difficult cases
Back to discussions
Expand all | Collapse all

Experience using tocilizumab or other IL-6/IL-6R signal pathway inhibitors (biologics or small molecules)

  • 1.  Experience using tocilizumab or other IL-6/IL-6R signal pathway inhibitors (biologics or small molecules)

    Posted 03-22-2020 18:18
    Edited by SITC Education 03-22-2020 18:24

    Click reply to post questions and discussions related to experiences using tocilizumab or other IL-6/IL-6R signal pathway inhibitors (biologics or small molecules).

    This discussion thread is intended to help organize the information and allow users to quickly find relevant conversations in the COVID-19 Implications for I-O Patient Management Forum. Discussion thread topics are not meant to be comprehensive or limiting and new threads as well as additional related questions within existing conversations are welcomed. 



    ------------------------------
    SITC Education
    Society for Immunotherapy of Cancer (SITC)
    Milwaukee WI
    ------------------------------


Related Content